Cipol-N Special Precautions

Cyclosporine should be used for therapeutic applications other than transplantation only by clinicians experienced in such use of immunosuppressive therapy.
Immunosuppression with cyclosporine may result in increased susceptibility to infection, including serious infections with fatal outcomes, and the possible development of lymphoma.
Immunosuppressed patients are at an increased risk for opportunistic infections, including reactivation of latent viral infections.
Because of the increased risk for skin cancer, patients should be advised to limit ultraviolet light exposure.
When necessary, (e.g., because of changes in oral absorption of the drug), dosage adjustment should be made to avoid toxicity resulting from high blood or plasma concentrations of the drug or to prevent possible organ rejection resulting from low concentrations.
Cyclosporine should be monitored routinely in allograft recipients and periodically in patients with rheumatoid arthritis.
Patients receiving cyclosporine should be informed of the necessity of routine laboratory testing (e.g., BUN and serum creatinine, bilirubin, and liver enzyme concentrations) for the assessment of renal and hepatic function.
Patients should be given careful dosage instructions, advised of the potential risks during pregnancy, and informed of the increased risk of neoplasia during cyclosporine therapy.
At high dosages, cyclosporine may cause nephrotoxicity and/or hepatotoxicity.